Navigation Links
CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Date:8/27/2007

on; risks associated with the Company's ability to receive approval from the FDA for the use of its cryoablation system to treat atrial fibrillation; risks associated with the Company's ability to successfully commercialize its cryoablation system in the United States and elsewhere if its cryoablation system is approved for use in the United States; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward- looking statements.

Contact:

CryoCor, Inc.

Gregory J. Tibbitts

Chief Financial Officer

(858) 909-2200

gtibbitts@cryocor.com

The Ruth Group

Nick Laudico / Zack Kubow (investors)

(646) 536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... QC , May 5, 2015 /CNW Telbec/ - ... Laval and known under the ... today the closing of the transaction previously announced on ... the issued and outstanding  shares of Orthoconcept (2008) inc.   ... issuing 500 000 common shares (TSXV: ERG) to the ...
(Date:5/5/2015)... EXTON, Pa. , May 5, 2015  The ... global leader in pharmacokinetic testing of drugs and safety ... Gum , Associate Director of Preclinical Studies, presented at ... in Vision and Ophthalmology (ARVO) in Denver, ... presentation was "Safety Assessment of a Novel, Cross-Linked, Bio-Absorbable ...
(Date:5/5/2015)... NIJMEGEN, the Netherlands , May ... company developing lower esophageal sphincter (LES) stimulation therapy ... positive safety and efficacy results. The results demonstrated ... heartburn and regurgitation and the "gold-standard" esophageal acid ... near-complete elimination of dependence on daily PPI medications. ...
Breaking Medicine Technology:Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3
... (MARKET WIRE) -- July 06, ... <a target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or ... the European Patent,Office has granted ... with claims related to,oral vaccination ...
... in The Lancet on TMC125, an Investigational ... /PRNewswire/ -- Data from two,ongoing Phase 3 ... adult patients with documented non-nucleoside reverse,transcriptase inhibitor ... undetectable viral load (defined as achieving,confirmed undetectable ...
Cached Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:5/5/2015)... (PRWEB) May 05, 2015 Private equity ... FZ LLC has announced that its dental stem cell ... Store-A-Tooth™ increased once again--in April, 2015 –and posted yet ... of increased record volume and represents a significant 54% ... dental stem cell biobank is conducted via the Store-A-Tooth ...
(Date:5/5/2015)... “Given that Hispanics are one in six people ... are a major step in the arsenal of facts documenting ... past 30 years, data have accumulated that the health of ... the urgency and the need to create new models of ... all,” said Jane L. Delgado, PhD, MS, President and CEO ...
(Date:5/5/2015)... May 05, 2015 The global lab ... 2020 from $3,474.2 Million in 2014, at an estimated ... segments the lab automation market on the basis of ... and region. On the basis of application, Lab Automation ... solutions, and proteomics solutions. Drug discovery is a major ...
(Date:5/5/2015)... The newly minted Regan Arts has just released a unique self-help ... from his 20 years working in the field of wilderness therapy. ... a parenting book and why this one, she replied, “What resonates ... it is a journey, not a destination...that the question is not ... together and sometimes not...that each of our struggles is unique. What ...
(Date:5/5/2015)... Skedans Systems a division ... the Skedans Sensor Collaboration Platform at AUVSI's Unmanned ... app developers, provides tooling to deliver real time information ... The Skedans Sensor Collaboration Platform is a single unified ... of Things, Web Real Time Communications (WebRTC), and commercial ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2
... patients with a devastating form of vasculitis who are in ... the disease flaring, according to a new study by investigators ... the first study to suggest that mental health is a ... disorders characterized by the inflammatory destruction of blood vessels. The ...
... Too few American doctors use oral food challenges to diagnose ... the gold standard, according to a new study. In ... if it causes an allergic reaction. This is done under ... identified 3,339 cases of food allergy. However, only 61.5 percent ...
... , SATURDAY, Nov. 5 (HealthDay News) -- Pregnancy ... study indicates. Lupus is a chronic inflammatory disease ... arthritis, fatigue and rashes. Lupus has been known to cause ... often emerging in their 20s and 30s when many women ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... test may not be accurate in identifying a gene that ... get. The Oncotype DX, marketed by Genomic Health, results ... to a study published Oct. 18 in the Journal ...
... Households Financial strain and competing priorities at ... readmissions of children with asthma from single-parent homes compared ... at the American College of Allergy, Asthma and Immunology ... The study, performed at Cincinnati Children,s Hospital Medical Center, ...
... , FRIDAY, Nov. 4 (HealthDay News) -- Online forums ... with their feelings of loss and isolation, according to a ... System found the women are often driven to the Internet ... or family. They noted that half of the women who ...
Cached Medicine News:Health News:Stress triggers disease flares in patients with vasculitis 2Health News:Stress triggers disease flares in patients with vasculitis 3Health News:'Food Challenges' Provide Best Allergy Diagnoses: Study 2Health News:Pregnancy Safe for Most Women With Lupus: Study 2Health News:Common Breast Cancer Gene Test May Be Flawed, Study Says 2Health News:Common Breast Cancer Gene Test May Be Flawed, Study Says 3Health News:New interventions, recommendations for controlling allergies & asthma in children 2Health News:New interventions, recommendations for controlling allergies & asthma in children 3Health News:New interventions, recommendations for controlling allergies & asthma in children 4Health News:New interventions, recommendations for controlling allergies & asthma in children 5Health News:Online Forums Can Help Women Cope With Pregnancy Loss 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: